

=====

Sequence Listing was accepted with existing errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: Thu Jul 26 16:44:24 EDT 2007

=====

Application No: 10539828 Version No: 1.1

Input Set:

Output Set:

Started: 2007-07-26 16:44:12.142
Finished: 2007-07-26 16:44:12.307
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 165 ms
Total Warnings: 1
Total Errors: 1
No. of SeqIDs Defined: 5
Actual SeqID Count: 5

Error code	Error Description
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <151>
W 213	Artificial or Unknown found in <213> in SEQ ID (5)

SEQUENCE LISTING

<110> INNATE PHARMA

<120> Pharmaceutical Compositions Having an Effect on the
Proliferation of NK Cells and a Method Using the Same

<130> B0207WO

<140> 10539828

<141> 2007-07-09

<150> US 60/435,344

<151> 23/12/2003

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 190

<212> PRT

<213> Homo sapiens

<400> 1

Met	Ala	Trp	Met	Leu	Leu	Leu	Ile	Leu	Ile	Met	Val	His	Pro	Gly	Ser
1				5					10					15	

Cys	Ala	Leu	Trp	Val	Ser	Gln	Pro	Pro	Glu	Ile	Arg	Thr	Leu	Glu	Gly
		20						25					30		

Ser	Ser	Ala	Phe	Leu	Pro	Cys	Ser	Phe	Asn	Ala	Ser	Gln	Gly	Arg	Leu
		35					40					45			

Ala	Ile	Gly	Ser	Val	Thr	Trp	Phe	Arg	Asp	Glu	Val	Val	Pro	Gly	Lys
	50					55					60				

Glu	Val	Arg	Asn	Gly	Thr	Pro	Glu	Phe	Arg	Gly	Arg	Leu	Ala	Pro	Leu
65					70					75					80

Ala	Ser	Ser	Arg	Phe	Leu	His	Asp	His	Gln	Ala	Glu	Leu	His	Ile	Arg
				85					90					95	

Asp	Val	Arg	Gly	His	Asp	Ala	Ser	Ile	Tyr	Val	Cys	Arg	Val	Glu	Val
			100					105					110		

Leu	Gly	Leu	Gly	Val	Gly	Thr	Gly	Asn	Gly	Thr	Arg	Leu	Val	Val	Glu
	115						120					125			

Lys	Glu	His	Pro	Gln	Leu	Gly	Ala	Gly	Thr	Val	Leu	Leu	Leu	Arg	Ala
	130					135					140				

Gly	Phe	Tyr	Ala	Val	Ser	Phe	Leu	Ser	Val	Ala	Val	Gly	Ser	Thr	Val
145					150					155					160

Tyr	Tyr	Gln	Gly	Lys	Cys	His	Cys	His	Met	Gly	Thr	His	Cys	His	Ser
				165					170						175

Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys Pro
180 185 190

<210> 2
<211> 120
<212> PRT
<213> Homo sapiens

<400> 2
Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Ser
1 5 10 15

Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu Ala Ile
20 25 30

Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val
35 40 45

Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu Ala Ser
50 55 60

Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg Asp Val
65 70 75 80

Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val Leu Gly
85 90 95

Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu Lys Glu
100 105 110

His Pro Gln Leu Gly Ala Gly Thr
115 120

<210> 3
<211> 19
<212> PRT
<213> Homo sapiens

<400> 3
Val Leu Leu Leu Arg Ala Gly Phe Tyr Ala Val Ser Phe Leu Ser Val
1 5 10 15

Ala Val Gly

<210> 4
<211> 33
<212> PRT
<213> Homo sapiens

<400> 4
Ser Thr Val Tyr Tyr Gln Gly Lys Cys His Cys His Met Gly Thr His
1 5 10 15

Cys His Ser Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys
20 25 30

Pro

<210> 5

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide derived
from natural sequence, useful for antiserum
production

<400> 5

Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Cys
1 5 10 15